NCT06960213Phase 3Recruiting

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

Study sponsor: ADARx Pharmaceuticals, Inc. · ADRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-11-30Estimated
Enrollment · participants90Estimated
Source updated2026-09-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: 30 Jun 2027. After: 30 Nov 2027.

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Efficacy of ADX-324 in preventing investigator-confirmed HAE attacks. After: Measure: Efficacy of ADX-324 in preventing HAE attacks.

Primary completion date changed

Before: 31 Dec 2026. After: 30 Jun 2027.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview